Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of SY-5007 in advanced solid tumors with RET alterations
CTR20210858Phase 2Active
- Sponsor
- Shouyao Holdings
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sotetinib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), Medullary Thyroid Cancer (MTC), sponsored by Shouyao Holdings. Started Jun 2021; status: active.
02
Drugs
sotetinib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on CTR20210858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210858.